VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Saturday, January 10, 2026

Stock Comparison

Berkshire Hathaway Inc. vs Vertex Pharmaceuticals Incorporated

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Berkshire Hathaway Inc.

BRK.B · New York Stock Exchange

Market cap (USD)$1.1T
Gross margin (TTM)28.7%
Operating margin (TTM)15.8%
Net margin (TTM)17.8%
SectorFinancials
IndustryInsurance - Diversified
CountryUS
Data as of2025-12-30
Moat score
64/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Berkshire Hathaway Inc.'s moat claims, evidence, and risks.

View BRK.B analysis

Vertex Pharmaceuticals Incorporated

VRTX · NASDAQ

Market cap (USD)$119B
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
IndustryBiotechnology
CountryUS
Data as of2026-01-08
Moat score
99/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Vertex Pharmaceuticals Incorporated's moat claims, evidence, and risks.

View VRTX analysis

Comparison highlights

  • Moat score gap: Vertex Pharmaceuticals Incorporated leads (99 / 100 vs 64 / 100 for Berkshire Hathaway Inc.).
  • Segment focus: Berkshire Hathaway Inc. has 11 segments (28.3% in Insurance (underwriting + investment income)); Vertex Pharmaceuticals Incorporated has 3 segments (99.9% in Cystic Fibrosis CFTR Modulators).
  • Primary market structure: Competitive vs Quasi-Monopoly. Pricing power: n/a vs Strong.
  • Moat breadth: Berkshire Hathaway Inc. has 17 moat types across 4 domains; Vertex Pharmaceuticals Incorporated has 7 across 4.

Primary market context

Berkshire Hathaway Inc.

Insurance (underwriting + investment income)

Market

Insurance and reinsurance (property and casualty + life/health), including float-funded investing

Geography

Global

Customer

Consumers and businesses (policyholders) and insurers (reinsurance cedents)

Role

Underwriter and reinsurer plus investment manager of float

Revenue share

28.3%

Vertex Pharmaceuticals Incorporated

Cystic Fibrosis CFTR Modulators

Market

CFTR modulator therapies for cystic fibrosis

Geography

U.S., Europe, Australia, Canada

Customer

Patients (via specialty pharmacies/payers); CF care centers

Role

Drug developer/manufacturer

Revenue share

99.9%

Side-by-side metrics

Berkshire Hathaway Inc.
Vertex Pharmaceuticals Incorporated
Ticker / Exchange
BRK.B - New York Stock Exchange
VRTX - NASDAQ
Market cap (USD)
$1.1T
$119B
Gross margin (TTM)
28.7%
n/a
Operating margin (TTM)
15.8%
n/a
Net margin (TTM)
17.8%
n/a
Sector
Financials
Healthcare
Industry
Insurance - Diversified
Biotechnology
HQ country
US
US
Primary segment
Insurance (underwriting + investment income)
Cystic Fibrosis CFTR Modulators
Market structure
Competitive
Quasi-Monopoly
Market share
n/a
70%-78% (reported)
HHI estimate
n/a
n/a
Pricing power
n/a
Strong
Moat score
64 / 100
99 / 100
Moat domains
Financial, Supply, Demand, Legal
Legal, Demand, Financial, Supply
Last update
2025-12-30
2026-01-08

Moat coverage

Shared moat types

Capacity MoatIP Choke PointService Field Network

Berkshire Hathaway Inc. strengths

Float PrepaymentBrand TrustPhysical Network DensityLong Term ContractsConcession LicensePermits Rights Of WayDesign In QualificationCapex Knowhow ScaleScale Economies Unit CostDistribution ControlTraining Org Change CostsPreferential Input AccessScope EconomiesCost Of Capital Advantage

Vertex Pharmaceuticals Incorporated strengths

Government Contracting RelationshipsSwitching Costs GeneralBenchmark Pricing PowerRegulated Standards Pipe

Segment mix

Berkshire Hathaway Inc. segments

Full profile >

Insurance (underwriting + investment income)

Competitive

28.3%

BNSF Railway (freight rail transportation)

Oligopoly

6.4%

Berkshire Hathaway Energy (regulated utilities, pipelines, renewables)

Monopoly

7.1%

Industrial products manufacturing (PCC, Lubrizol, IMC, Marmon, etc.)

Oligopoly

9.7%

Building products & housing (Clayton Homes, Shaw, Johns Manville, Benjamin Moore, etc.)

Competitive

7.2%

Consumer products manufacturing (Duracell, Forest River, apparel/footwear, toys, etc.)

Competitive

4%

Service businesses (FlightSafety, NetJets, TTI, Dairy Queen, etc.)

Competitive

5.6%

Retailing businesses (Berkshire Hathaway Automotive, home furnishings, jewelry, See's, etc.)

Competitive

5.2%

Pilot Travel Centers (travel centers + wholesale fuel marketing)

Oligopoly

12.6%

McLane (wholesale distribution to convenience stores and restaurants)

Oligopoly

14%

Holding company capital allocation and investing

Competitive

n/a

Vertex Pharmaceuticals Incorporated segments

Full profile >

Cystic Fibrosis CFTR Modulators

Quasi-Monopoly

99.9%

Hemoglobinopathies Gene Therapy (CASGEVY)

Oligopoly

0.1%

Acute Pain (JOURNAVX)

Competitive

n/a

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.